Table 1 Characteristics of animal experiments
First author Year | Location | Animal (sex, strain, weight) | Number of each group | Modeling method | Modeling duration | Type and source of MSC | Way of MSC administrated | Times of treatment | Dose of MSC | Parameter |
|---|---|---|---|---|---|---|---|---|---|---|
Forte; 2015 [16] | Italy | Male, C57BL/6 mice, NA | DSS + PBS (n = 4) DSS + MSC (n = 4) | DSS (1.5%) | 9 | hASC | Irrigation | 3 | 1 × 106 cells/mouse/time | DAI, HS |
Chao; 2016 [17] | China | Male, BALB/c mice, NA | TNBS + 50% ethanol + MSC (n = 20) TNBS + 50% ethanol (n = 20) | TNBS (5%) | 8 | hUC-MSC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS, MPO activity |
Gao; 2020 [18] | China | Male, Wistar rat, 150–200 g | TNBS + 50% ethanol + MSC (n = 8) TNBS + 50% ethanol (n = 8) | TNBS (2%) | 8 | rASC | Tail vein injection | 1 | 1 × 107 cells/mouse/time | DAI, colon length |
Nam; 2015 [19] | South Korea | Female, C57BL/6, NA | DSS + PBS (n = 10) DSS + MSC (n = 10) | DSS (3.5%) | 7 | mBM-MSC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | DAI |
Yang; 2018 [20] | China | Female, C57 mice, 19–21 g | DSS + PBS (n = 10) DSS + MSC (n = 10) | DSS (1.5%) | 6 | hUC-MSC | Intraperitoneal injection | 2 | 2 × 106 cells/mouse/time | DAI, HS |
Gonzalez-Rey; 2008 [21] | Spain | NA, C57BI/6 mice, NA | DSS + PBS (n = 14) DSS + MSC (n = 14) | DSS (5%) DSS (3%) | 7 34 | hASC | Intraperitoneal injection | 1 2 | 1 × 106 cells/mouse/time | DAI, colon length, HS, MPO activity |
Lin; 2015 [22] | China | Male, C57BL/6 mice, NA | DSS + PBS (n = 10) DSS + MSC (n = 10) | DSS (5%) | 7 | hUC-MSC | Intraperitoneal injection | 1 | 2 × 106 cells/mouse/time | DAI, colon length, MPO activity |
Banerjee; 2015 [23] | Italy | Male, NOD.CB17-Prkdcscid/J mice, 18–25 g | DSS + PBS (n = 5) DSS + MSC (n = 5) | DSS (3.5%) | 7 | hUC-MSC | Tail vein injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS, MPO activity |
Song; 2018 [24] | South Korea | Male, C57BL/6 J mice, NA | DSS + PBS (n = 6) DSS + MSC (n = 6) | DSS (3%) | 7 | cAT-MSC | Intraperitoneal injection | 1 | 2 × 106 cells/mouse/time | DAI, colon length, HS |
Lim; 2021 [25] | South Korea | Female, C57BL/6 mice, NA | DSS + PBS (n = 4) DSS + MSC (n = 4) | DSS (2.5%) | 9 | mBM-MSC | Intraperitoneal injection | 1 | 3 × 106 cells/mouse/time | DAI, colon length |
Miyamoto; 2017 [26] | Japan | Male, Sprague–Dawley rats, NA | TNBS + 30% ethanol + MSC (n = 9) TNBS + 30% ethanol + PBS (n = 9) | TNBS (45 mg/kg) | 7 | hAMSC | Penile vein injection | 1 | 1 × 106 cells/mouse/time | HS |
Ikarashi; 2017 [27] | Japan | Male, C57BL/6 mice, NA | DSS + PBS (n = 7) DSS + MSC (n = 16) | DSS (2.5%) | 7 | hASC hUC-MSC | Intravenous injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Li; 2020 [28] | China | Female, C57BL/6 mice, 18-22 g | DSS + PBS (n = 12) DSS + MSC (n = 12) | DSS (3%) | 8 24 | hUC-MSC | Intraperitoneal injection | 2 4 | 2 × 106 cells/mouse/time | DAI, MPO activity, colon length, HS |
Lee; 2016 [29] | South Korea | Female, C57BL/6 mice, 17-21 g | DSS + PBS (n = 5) DSS + MSC (n = 5) | DSS (3%) | 30 | mBM-MSC | Intravenous injection | 3 | 1 × 107 cells/mouse/time | Colon length, HS |
Jo; 2019 [30] | South Korea | Female, C57BL/6 mice, NA | DSS + PBS (n = 5) DSS + MSC (n = 5) | DSS (3%) | 20 | mBM-MSC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | Colon length, HS |
Heidari; 2018 [31] | Iran | Female, C57BL/6 mice, 18–22 g | DSS + PBS (n = 5) DSS + MSC (n = 5) | DSS (2%) | 33 | mASC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Kawata; 2019 [32] | Japan | Male, C57BL/6 mice, NA | DSS + PBS (n = 5) DSS + MSC (n = 7) | DSS (2.5%) | 7 | hASC | Intravenous injection | 1 | 1 × 106 cells/mouse/time | DAI, colon length, HS |
Yu; 2017 [33] | South Korea | Male, C57BL/6 mice, 18–25 g | DSS + PBS (n = 9) DSS + MSC (n = 18) | DSS (1.5%) | 30 | hTMSC | Intraperitoneal injection | 2 4 | 1 × 106 cells/mouse/time | Colon length |
Lu; 2019 [34] | China | NA, C57BL/6 mice, NA | DSS + PBS (n = 6) DSS + MSC (n = 6) | DSS (3%) | 26 | hGMSC | Tail vein injection | 1 | NA | Colon length |
Tanaka; 2010 [35] | Japan | NA, Lewis rat, 180–220 g | DSS + PBS (n = 10) DSS + MSC (n = 10) | DSS (4%) | 7 | rBM-MSC | Tail vein injection | 3 | 2 × 104 cells/g/time (the second and third injection) 2 × 103 cells/g/time (the first injection) | HS |
Molendijk; 2016 [36] | The Netherlands | Female, C57BL/6Jico mice, NA | DSS + PBS (n = 7) DSS + MSC (n = 21) | DSS (1.25%) | 7 | mBM-MSC | Local injection | 1 | 0.5 × 106 cells/mouse/time 2 × 106 cells/mouse/time | Colon length |
Liang; 2011 [37] | China | Male, BALB/c mice, 20 g | TNBS + 50% ethanol + MSC (n = 6) TNBS + 50% ethanol (n = 6) | TNBS (100 mg/kg) | 5 | hUC-MSC | Intravenous injection | 2 | 1 × 106 cells/mouse/time | HS, MPO activity |
Fuenzali; 2016 [38] | Chile | Female, C57BL/6 mice, NA | DSS + PBS (n = 7) DSS + MSC (n = 7) | DSS (2.5%) | 7 | hUC-MSC | Intraperitoneal injection | 2 | 1 × 106 cells/mouse/time | Colon length |
Li; 2013 [39] | China | NA, C57Bl/6 mice, NA | DSS + PBS (n = 8) DSS + MSC (n = 16) | DSS (4%) | 7 | hUC-MSC hBM-MSC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS, colon length, MPO activity |
Tanaka; 2008 [40] | Japan | Male, Lewis rats, approximately 200 g | DSS + PBS (n = 5) DSS + MSC (n = 5) | DSS (4%) | 7 | rBM-MSC | Tail vein injection | 1 | 5 × 106 cells/mouse/time | Colon length |
Nikolic; 2018 [41] | Serbia | NA, C57BL/6 mice, 19–21 g | DSS + PBS (n = 35) DSS + MSC (n = 35) | DSS (3%) | 7 | mBM-MSC | Tail vein injection | 3 | 2 × 106 cells/mouse/time | HS, colon length |
Nan; 2018 [42] | China | Male, Sprague–Dawley rats, 160–180 g | TNBS + 50% ethanol + MSC (n = 8) TNBS + 50% ethanol (n = 8) | TNBS (NA) | 7 | rBM-MSC | Tail vein injection | 1 | 5 × 106 cells/mouse/time | Colon length, HS |
Xie; 2017 [43] | China | NA, BALB/c mice, NA | TNBS + 50% ethanol + MSC (n = 30) TNBS + 50% ethanol (n = 15) | TNBS (3%) | 3 | mBM-MSC mASC | Intraperitoneal injection | 1 | 1 × 106 cells/mouse/time | HS |